This federal Project Grant award, totaling $872,684.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to use single-cell multi-omic profiling techniques to investigate the role of transcriptionally active HIV-infected cells in driving chronic immune activation, despite effective antiretroviral therapy (ART). The research aims to identify and characterize the...
This $884,322 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Fred Hutchinson Cancer Center supports research to study the mechanisms that create and sustain the HIV reservoir, a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The project will use a mathematical modeling approach to integrate existing and novel...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to investigate the mechanisms by which defective HIV proviruses in CD4+ T cells and macrophages perpetuate chronic inflammation and contribute to HIV comorbidities. The total funding amount is $765,274, and the award period runs from August 22, 2024 to June 30, 2029. The research aims to: 1) determine...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $234,115 to The Johns Hopkins University to conduct research on the HIV latent reservoir. The key objectives are to: 1) fully characterize the clonality distribution of intact and defective HIV proviruses in people living with HIV (PLWH) on antiretroviral therapy (ART), and 2) develop mathematical models to...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 (Allergy and Infectious Diseases Research), supports research focused on understanding the role of intestinal microfold (M) cells in creating an environment that fosters HIV persistence and reactivation. The $1,658,792 award, with a performance period from May 2024 to April 2025, will investigate whether the interaction between M cells and CD4+ T cells...
This Project Grant award, valued at $3,800,169.08 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into the development of anti-proliferative therapies to limit long-term persistence of the HIV reservoir. The award aims to identify and optimize anti-proliferative drug regimens that can be administered early in the course of HIV/SIV infection to reduce the size and alter...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify effective HIV-1 vaccine strategies. The project aims to determine the optimal pathway from common B-cell receptors (BCRs) with long, tyrosine-sulfated heavy-chain CDR3s to broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein apex. The $1,696,146 award, provided...
The Project Grant award in the amount of $500,475.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate the host-dependent mechanisms that guide the longitudinal dynamics of sites of SIV (Simian Immunodeficiency Virus) integration. The research aims to generate an atlas of SIV integration sites, delineate the impact of host factors on SIV...
The federal Project Grant award of $500,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify and modulate molecular pathways that govern T cell antigen sensitivity in persons with HIV (PWH). The key objectives are to: 1) Elucidate regulatory mechanisms governing antigen-refractory HIV-specific CD8+ T cells, including their maintenance through epigenetic control; 2) Define the...
The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $2,993,935 Project Grant to the Children's Hospital Corporation (doing business as Boston Children's Hospital) for a research project titled "HIV-1 Membrane Fusion and Inhibition". The key objectives of this five-year (May 2024 - March 2029) research project are to: 1) Determine the structure of the HIV-1 fusion complex...
This Project Grant award under the National Institutes of Health's Allergy and Infectious Diseases Research program (CFDA 93.855) provides $3,471,592 to Brigham & Women's Hospital Inc. to conduct research on the immune selection of HIV-1 reservoir cells in human clinical trials. The research aims to identify specific immunological pathways and vulnerabilities of the HIV-1 reservoir cell pool that can be exploited in future interventions to limit HIV-1 persistence. The award period is from May 1, 2024, to March 31, 2029.
The research involves leveraging samples from three recently conducted clinical trials to apply novel single-genome/single-cell analytical techniques. This includes using single-cell phenotypic profiling to analyze the interplay between viral reservoir cells and immune effector cells, performing single-cell chromosomal integration site monitoring and phenotyping, and investigating immune selection pressure against HIV-1 reservoir cells. The research is being conducted in collaboration with a sub-awardee, the Massachusetts General Hospital, which is responsible for performing comprehensive epigenetic assays and immune response analysis.